Background Oxidized low density lipoproteins (o-LDLP) are essential for progression of metabolic syndrome and development of its clinical manifestations. There are some data than o-LDLP are important in the pathogenesis of osteoarthritis (OA) through apoptosis of chondrocytes. Experiments in rat articular chondrocytes culture showed that o-LDLP may cause death of this cells. Avocado and soya unsaponifiables (ASU) is common medicine in OA. We suppose ASU may influence on lipid metabolism and their efficiency may be connected with o-LDLP level in OA.
Objectives To study serum o-LDLP concentration in OA and to improve results of ASU therapy in OA patients depending on the o-LDLP level in serum.
Methods We examined 175 people: 130 OA patients and 45 healthy donors. The patients receiving ASU (Piascledin, Expanscience, France, n=40) 300 mg per day for 3 months were divided into 2 groups: The first (1-st) group (24 OA patients) had increased o-LDLP level (more than 168 ng/ml). The second (2-nd) group (16 patients) had normal o-LDLP level. The level o-LDLP were determined with ELISA- test (Biomedica Gruppe, Oxidized LDL, cat No. 20042) before and after treatment.
Results o-LDLP concentration in serum of healthy individuals was 114,3±4,2 ng/ml (here and further M±m). The level of normal o-LDLP values defined as M±2 standard deviation was from 60 to 168 ng/ml. Elevated o-LDLP levels in OA patients sera was detected in 78 (60%) (difference with healthy subjects, p<0,001). o-LDLP concentration in OA patients was 252.2+3.4 ng/ml (difference with healthy subjects =0.0014). After ASU therapy we revealed improvement of the functional status in OA patients. ASU treatment resulted in decreasing of o-LDLP level (p<0,01) and C reactive protein concentration (p<0,01) in serum. In this study we determined improvement of a condition in 95.83% of patients in 1-st subgroup, and in only 50.0% in 2-nd subgroup.
Conclusions Thus, we noted increased o-LDLP level in OA patients. Elevated o-LDLP level was detected in 60.0% of patients that were significantly more than that of healthy individuals (4.4%). Efficacy of ASU therapy in OA depends on the initial level of o-LDLP in serum. ASU are more effective at the level of serum o-LDLP more than 168 ng/ml. Hence, determination of o-LDLP in OA patients may increase ASU efficiency.
Disclosure of Interest None declared